The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): Updated phase 2 safety and efficacy results.
 
Lasika C. Seneviratne
Consulting or Advisory Role - AstraZeneca; Novartis
Speakers' Bureau - Novartis
 
Kathleen Kiernan Harnden
Honoraria - Clinical Care Options; E-Health Now
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/UCB Japan; Merck; Seagen
 
Sibel Blau
Employment - Northwest Medical Specialties
Leadership - Northwest Medical Specialties; Quality Cancer Care Alliance
Stock and Other Ownership Interests - All4cure (I); Northwest Medical Specialties
Honoraria - American Journal of Managed Care; Cardinal Health; Novartis; Puma Biotechnology
Consulting or Advisory Role - Billion to One; IntegraConnect
Research Funding - Northwest Medical Specialties
Expert Testimony - Northwest Medical Specialties
Travel, Accommodations, Expenses - Northwest Medical Specialties; Quality Cancer Care Alliance
Other Relationship - All4Cure (I); Exigent Research; Northwest Medical Specialties; Quality Cancer Care Alliance
 
Michael A. Danso
Honoraria - Amgen
Consulting or Advisory Role - Immunomedics; Novartis; Pfizer; Seagen
 
David Berz
Honoraria - AstraZeneca; Caris Life Sciences; EMD Serono; Jazz Pharmaceuticals; Mirati Therapeutics; OncoCyte; Sun Pharma
Consulting or Advisory Role - Jazz Pharmaceuticals; Sun Pharma
Speakers' Bureau - AstraZeneca; Biocept; Boehringer Ingelheim; Caris Life Sciences; EMD Serono; Jazz Pharmaceuticals; Mirati Therapeutics; natera; Novartis; OncoCyte; Sun Pharma
 
Delia Constanza Guaqueta
Consulting or Advisory Role - Lilly
 
John F. Schwerkoske
Employment - Minnesota Oncology
Leadership - Minnesota Oncology
 
Joyce O'Shaughnessy
Honoraria - Abbvie; Agendia; Amgen; Aptitude Health; AstraZeneca; BioNTech; Byondis; Carrick Therapeutics; Daiichi Sankyo; DAVA Oncology; Eisai; Fishawack Health; G1 Therapeutics; Genentech; Genzyme; Gilead Sciences; GlaxoSmithKline; Lilly; Loxo/Lilly; Merck; Novartis; Ontada/McKesson; Pfizer; Pierre Fabre; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Stemline Therapeutics; Taiho Oncology; Veru
Consulting or Advisory Role - Abbvie; Agendia; Amgen; Aptitude Health; AstraZeneca; BioNTech; Byondis; Carrick Therapeutics; Daiichi Sankyo; DAVA Oncology; Eisai; Fishawack Health; G1 Therapeutics; Genentech; Genzyme; Gilead Sciences; GlaxoSmithKline; Lilly; Loxo/Lilly; Merck; Novartis; Ontada/McKesson; Pfizer; Pierre Fabre; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Stemline Therapeutics; Taiho Oncology; Veru
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Pfizer; Seagen
Travel, Accommodations, Expenses - Agendia; Aptitude Health; AstraZeneca; Daiichi Sankyo; DAVA Oncology; Eisai; Lilly; Loxo/Lilly; Merck; Novartis; Pfizer; Roche; Seagen
 
Debra A. Patt
Employment - MedNax (I); Texas Oncology; The US ONcology Network
Leadership - Mednax (I); Texas Oncology
Stock and Other Ownership Interests - Mednax (I)
Consulting or Advisory Role - Amgen; AstraZeneca; Pfizer; Roche
Research Funding - Eisai (Inst); Lilly (Inst); Merck (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Amgen; Pfizer
(OPTIONAL) Uncompensated Relationships - Navigating Cancer
 
Aditya Bardia
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Genentech; Genentech/Roche (Inst); Gilead Sciences; Gilead Sciences (Inst); Innocrin Pharma (Inst); Lilly; Lilly (Inst); Menarini; Menarini (Inst); Merck; Mersana; Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Radius Health (Inst); Sanofi
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Genentech (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Sanofi (Inst)
 
Kelly Elizabeth McCann
Honoraria - OncLive/MJH Life Sciences; PER
Consulting or Advisory Role - Lilly; Puma Biotechnology; Tersera
Speakers' Bureau - Lilly
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); H3 Biomedicine (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); Olema Oncology (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Lilly
 
Andrew Paul Beelen
Employment - G1 Therapeutics
Stock and Other Ownership Interests - G1 Therapeutics
 
Jingshan Zhang
Employment - G1 Therapeutics
Stock and Other Ownership Interests - G1 Therapeutics
 
John S. Yi
Employment - G1 Therapeutics
Stock and Other Ownership Interests - G1 Therapeutics
Travel, Accommodations, Expenses - G1 Therapeutics; G1 Therapeutics
 
Sara A. Hurvitz
Stock and Other Ownership Interests - ROM Tech (I)
Research Funding - Ambryx (Inst); Amgen (Inst); Arvinas (Inst); AstraZeneca/Daiichi Sankyo (Inst); Bayer (Inst); Biomarin (Inst); Cascadian Therapeutics (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dantari (Inst); Dignitana (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Greenwich LifeSciences (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merrimack (Inst); Novartis (Inst); OBI Pharma (Inst); Orinove (Inst); Orum (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Pieris Pharmaceuticals (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Samumed (Inst); sanofi (Inst); Seagen (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Lilly
Other Relationship - Pfizer; Roche
 
Mabel Alejandra Mardones
Consulting or Advisory Role - Agendia; AstraZeneca; bioTheranostics; Epic Sciences; Genentech/Roche; Gilead Sciences; Myriad Genetics; Sanofi; Seagen
Speakers' Bureau - Merarini; Puma Biotechnology; Seagen